Chardan Capital Maintains Buy on SAB Biotherapeutics, Raises Price Target to $16

Benzinga Newsdesk www.benzinga.com Positive 85.7%

Neg 0% Neu 0% Pos 85.7%

Chardan Capital analyst Keay Nakae maintains SAB Biotherapeutics (NASDAQ:SABS) with a Buy and raises the price target from $14 to $16.